Leerink Partnrs Issues Pessimistic Outlook for PTCT Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Research analysts at Leerink Partnrs cut their FY2026 EPS estimates for PTC Therapeutics in a research note issued on Sunday, November 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings of ($2.42) per share for the year, down from their previous forecast of ($1.66). The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The company had revenue of $211.01 million for the quarter, compared to analyst estimates of $177.42 million. During the same quarter last year, the company posted ($1.39) EPS. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS.

Other research analysts have also recently issued research reports about the stock. The Goldman Sachs Group increased their target price on shares of PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and issued a $118.00 target price on shares of PTC Therapeutics in a research report on Wednesday, September 3rd. Citigroup boosted their target price on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Finally, Truist Financial increased their price target on PTC Therapeutics from $80.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $75.40.

PTC Therapeutics Stock Up 1.1%

NASDAQ:PTCT opened at $76.46 on Wednesday. PTC Therapeutics has a twelve month low of $35.95 and a twelve month high of $78.74. The stock’s 50-day simple moving average is $66.68 and its 200 day simple moving average is $55.20. The firm has a market capitalization of $6.14 billion, a PE ratio of 10.97 and a beta of 0.60.

Insider Activity

In related news, Director Emma Reeve sold 25,562 shares of the business’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $65.96, for a total value of $1,686,069.52. Following the sale, the director owned 10,332 shares of the company’s stock, valued at $681,498.72. The trade was a 71.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Mark Elliott Boulding sold 24,585 shares of the stock in a transaction on Friday, September 12th. The shares were sold at an average price of $61.34, for a total value of $1,508,043.90. Following the completion of the sale, the vice president owned 103,901 shares of the company’s stock, valued at $6,373,287.34. The trade was a 19.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 264,807 shares of company stock valued at $16,760,813. 5.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds have recently made changes to their positions in PTCT. AlphaQuest LLC raised its holdings in PTC Therapeutics by 337.7% during the 2nd quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 6,102 shares during the last quarter. Sector Gamma AS increased its position in shares of PTC Therapeutics by 41.4% during the first quarter. Sector Gamma AS now owns 92,250 shares of the biopharmaceutical company’s stock worth $4,701,000 after buying an additional 27,000 shares during the period. Deutsche Bank AG raised its stake in PTC Therapeutics by 262.1% during the first quarter. Deutsche Bank AG now owns 341,724 shares of the biopharmaceutical company’s stock worth $17,414,000 after buying an additional 247,346 shares during the last quarter. Cerity Partners LLC bought a new position in PTC Therapeutics during the first quarter worth $641,000. Finally, Nuveen LLC acquired a new position in PTC Therapeutics in the first quarter valued at $51,427,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.